Redefining Expectations
in Rare Disease

Amicus Therapeutics has entered into a definitive agreement to be acquired by BioMarin. This agreement will enable our therapies to reach even more patients around the world, faster.
Read more here.

About Amicus

We are a leading, global rare-disease focused biotechnology company with a clear and compelling mission: to develop and deliver transformative medicines for people living with rare diseases.

We are guided by people living with rare diseases across the globe.

Get to know some of them: